Company Encyclopedia
View More
name
Bullfrog AI
BFRG.US
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases; and Modified HSV-1, which is in the discovery phase, for the treatment of modified colorectal cancer. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease.
70.40 B
BFRG.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
Health Care TechnologyIndustry
Industry Ranking40/44
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-234.47%E
    • Profit Margin-5770.67%E
    • Gross Margin18.43%D
  • Growth ScoreD
    • Revenue YoY0.00%C
    • Net Profit YoY-2.55%C
    • Total Assets YoY-41.28%E
    • Net Assets YoY-49.16%E
  • Cash ScoreD
    • Cash Flow Margin-1.73%D
    • OCF YoY0.00%C
  • Operating ScoreE
    • Turnover0.03E
  • Debt ScoreB
    • Gearing Ratio28.08%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BullFrog AI and Myriad Uranium Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    RedChip Companies will air interviews with BullFrog AI and Myriad Uranium on Bloomberg TV's "Small Stocks, Big Money" show. BullFrog AI's CEO will discuss their AI-driven platform for drug development, highlighting collaborations and revenue projections. Myriad Uranium's CEO will outline their uranium exploration strategy, emphasizing recent drilling successes and future plans. Both companies aim for scalable growth and shareholder value. The show airs on November 29 at 7 p.m. ET.

    Acceswire·
    US
    BFRG
    +5.50%
    US
    UEC
    +9.50%
    US
    MYGN
    0.00%
    Acceswire·
    US
    BFRG
    +5.50%
    US
    UEC
    +9.50%
    US
    MYGN
    0.00%

    BullFrog AI Unveils Whitepaper Showcasing AI Platform for Drug Discovery

    BullFrog AI Holdings Inc. has published a whitepaper detailing its AI-driven technologies in bioinformatics, focusing on the BullFrog Data Networks® and bfLEAP® platform. The whitepaper highlights advancements in drug discovery, including improved target identification, biomarker discovery, and patient stratification, using methods developed at Johns Hopkins Applied Physics Laboratory. The document is available for download.

    Reuters·
    US
    BFRG
    +5.50%
    Reuters·
    US
    BFRG
    +5.50%

    Bullfrog AI | 10-Q: FY2025 Q3 Revenue: USD 83.41 K

    LB filings·
    US
    BFRG
    +5.50%
    LB filings·
    US
    BFRG
    +5.50%

    BullFrog AI Approves Key Stockholder Proposals

    BullFrog AI Holdings, Inc. (BFRG) announced the approval of key stockholder proposals during a Special Meeting on October 22, 2025. The approved proposals include issuing 20% or more of the company’s common stock, a reverse stock split, and increasing shares under the 2022 Equity Incentive Plan by 750,000. These changes are expected to enhance the company's operational flexibility and market positioning. BullFrog AI focuses on using AI for drug development and precision medicine, with a current market cap of $13.73M and an average trading volume of 217,786.

    Tip Ranks·
    US
    BFRG
    +5.50%
    Tip Ranks·
    US
    BFRG
    +5.50%

    Bullfrog AI files to sell 5M shares of common stock for holders

    Bullfrog AI (NASDAQ:BFRG) filed to sell 5M shares of common stock for holders. This preliminary prospectus is not an offer to sell. Filing More on Bullfrog AI Holdings, Inc. Financial information for Bullfrog AI Holdings, Inc.

    MSN·
    US
    BFRG
    +5.50%
    MSN·
    US
    BFRG
    +5.50%
    © 2025 Longbridge｜Disclaimer